13 hrs ago
The Motley Fool
GlaxoSmithKline: The World's Biggest Biotech Startup?
On paper, it shares many of the typical characteristics of a big pharma company: attractive dividend, strong free cash flow, and several drugs in its pipeline.
Tue Dec 17, 2013
Pfizer Settles Viagra Patent Litigation With Teva
Pfizer announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of ViagraA to treat erectile dysfunction , relating to Pfizer's patent covering the use of ViagraA to treat erectile dysfunction , which expires in April 2020 .
Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business
By mutual agreement, Amy Schulman Steps down as General Counsel and member of Pfizer's Executive Leadership Team; will not assume role as head of Vaccines, Oncology and Consumer Healthcare business )--Pfizer Inc. named Albert Bourla as Group President of the Vaccines, Oncology and Consumer Healthcare business effective January 1, 2014.
Mon Dec 16, 2013
Court Report -- December 15, 2013
Pfizer Inc. et al. v. Hetero USA Inc. et al. 1:13-cv-02021; filed December 11, 2013 in the District Court of Delaware Pfizer Inc. et al. v.
Pfizer Declares First-Quarter 2014 Dividend
Board of Directors Approves Increase in Quarterly Cash Dividend to $0.26 Per Share NEW YORK -- -- The board of directors of Pfizer Inc. today declared a 26-cent first-quarter 2014 dividend on the company's common stock, payable March 4, 2014 , to shareholders of record at the close of business on February 7, 2014 .
Availability rate in Greater Boston's lab space rises in Q3
The amount of available space in Greater Boston's biotechnology lab market increased slightly at the close of the third quarter, in part, due to the consolidation of space by pharmaceutical giants Pfizer and Vertex Pharmaceuticals .
InVivo Therapeutics Appoints Steven McAllister as Interim CFO
InVivo Therapeutics Holdings Corp. today announced the appointment of Steven McAllister as Interim Chief Financial Officer, effective December 31, 2013.
Fri Dec 13, 2013
"Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022" Published
Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible.
Wed Dec 11, 2013
Fed Fear: Dow Tumbles 130 Points, S&P 500 Off More Than 1%
If yesterday's market selling was a trickle, today was like a pipe bursting, as Nike , United Health Group and Pfizer tumbled.
Traders Watch List - Tower Group International, Ltd (NASDAQ:TWGP),...
PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more.
Mon Dec 09, 2013
Wall St. Cheat Sheet
Pfizer Needs an Aspirin After Supreme Court Rejects Appeal
The U.S. Supreme Court on Monday rejected an appeal from Pfizer Inc. , leaving in place a $142 million settlement the pharmaceutical company must pay to the Kaiser Foundation on the grounds that Pfizer falsely marketed an epilepsy drug called Neurontin.
Wed Dec 04, 2013
Pfizer Expands Clinical Trial Data Access Policy, Launches Data Access Portal
Pfizer Inc. today announced an update of its clinical trial data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials.
Bullish Stocks Commentary: Pfizer Inc, Zynga Inc, OCZ Technology...
Market Buzz Report, a leading penny stock newsletters provider, issues major news alert for Pfizer Inc. , Zynga Inc , OCZ Technology Group Inc. , EnteroMedics Inc .
Tue Dec 03, 2013
US stocks fall for 2nd day in a row
NEW YORK: US stocks on Tuesday fell for a second day in a row as speculation increased that the US Federal Reserve will soon scale back its bond-buying programme.
Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals
Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, commercial-stage pharmaceutical company focused on prescription Medical Foods, today announced the election of Francesco Granata, M.D., to its Board of Directors.
Mon Dec 02, 2013
Pfizer Inc. Acquires Polocard, Poland??'s Leading Over-The-Counter Heart Attack Prevention Brand
Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin , and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.
The Motley Fool
Biotech Week in Review
Although this rumor started well before this regulatory meeting, I previously said the rumors would only grow stronger if Vimizim was approved.
Sat Nov 30, 2013
GlaxoSmithKline focusing on Cambridge
The English drug firm GlaxoSmithKline has joined other major pharmaceutical companies, including Pfizer Inc., by announcing its intent to focus new attention on innovation centers including Cambridge, Mass.
Thu Nov 28, 2013
Molecular causes of transcriptional response: a Bayesian prior knowledge approach
A key question in this setting is as follows: what intermediate molecular perturbations gave rise to the observed transcriptional changes? Regulatory programs are not exclusively governed by transcriptional changes but also by protein abundance and post-translational modifications making direct causal inference from data difficult.
Mon Nov 25, 2013
Wall St. Cheat Sheet
Pfizer to Wed Indian Operations and Wyeth's India Unit
Pharmaceutical giant Pfizer Inc. acquired its competitor Wyeth in 2009 as a part of $68 billion dollar deal, but since then, the Indian units of both companies have remained separate entities on the Indian domestic stock exchange.